Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of
GlobeNewswireApr 11 07:30 ET
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose mo
Simply Wall StApr 5 08:00 ET
Anavex Life Sciences(AVXL.US) Officer Sells US$374.97K in Common Stock
$Anavex Life Sciences(AVXL.US)$ Officer MISSLING CHRISTOPHER U sold 73,380 shares of Common Stock on Mar 28, 2024 at an average price of $5.11 for a total value of $374.97K.Source: Announcement What i
moomoo NewsApr 1 18:41 ET
Form 144 | Anavex Life Sciences(AVXL.US) Officer Proposes to Sell 371.3K in Common Stocks
SEC FILLINGS DISCLOSED/ Mar 28, $Anavex Life Sciences(AVXL.US)$ Officer MISSLING CHRISTOPHER U intends to sell 73,380 shares of its common stock on Mar 28, with a total market value of approximately $
moomoo NewsMar 28 08:39 ET
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of
GlobeNewswireMar 25 07:30 ET
Express News | Anavex Life Sciences Announced That The First Patient In Its Phase 2 Study Of ANAVEX3-71 For Schizophrenia Has Been Screened Ahead Of Schedule
Moomoo 24/7Mar 18 07:35 ET
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX3-71 in Schizophrenia
First patient screened ahead of schedule Trial to investigate positive, negative, and cognitive domains of schizophrenia ANAVEX3-71's differentiated dual novel mechanism of action offers the potential to
GlobeNewswireMar 18 07:30 ET
AVLX, SGH and ETNB Are Among Pre Market Losers
Seeking AlphaMar 15 16:48 ET
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of
GlobeNewswireFeb 26 07:30 ET
Analysts Offer Insights on Healthcare Companies: Anavex Life Sciences (AVXL), PolyPid (PYPD) and Nyxoah (NYXH)
TipRanksFeb 15 06:30 ET
Earnings Call Summary | Anavex Life Sciences(AVXL.US) Q1 2024 Earnings Conference
The following is a summary of the Anavex Life Sciences Corp. (AVXL) Q1 2024 Earnings Call Transcript:Financial Performance:Anavex Life Sciences reported a cash position of $143.8 million for Q1 2024,
moomoo AIFeb 7 13:52 ET · Conference Call
Buy Rating Affirmed for Anavex Life Sciences Amid Positive Alzheimer's Program Outlook and Financial Stability
TipRanksFeb 7 11:55 ET
Anavex Life Sciences GAAP EPS of -$0.11 Beats by $0.04
Seeking AlphaFeb 7 07:35 ET
Anavex Life Sciences 1Q Loss/Shr 11c >AVXL
Anavex Life Sciences 1Q Loss/Shr 11c >AVXL
Dow JonesFeb 7 07:30 ET
Press Release: Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update
Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIR
Dow JonesFeb 7 07:30 ET
Anavex Life Sciences Had Cash and Cash Equivalents of $143.8M at Dec 31 >AVXL
Anavex Life Sciences Had Cash and Cash Equivalents of $143.8M at Dec 31 >AVXL
Dow JonesFeb 7 07:30 ET
Anavex Life Sciences Q1 2024 Earnings Preview
Seeking AlphaFeb 6 13:14 ET
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of
GlobeNewswireFeb 1 07:30 ET
Peering Into Anavex Life Sciences's Recent Short Interest
Anavex Life Sciences's (NYSE:AVXL) short percent of float has risen 10.79% since its last report. The company recently reported that it has 20.07 million shares sold short, which is 25.26% of all regu
BenzingaJan 24 13:45 ET
Anavex Life Sciences (AVXL) Upgraded to Strong Buy: Here's Why
Yahoo FinanceJan 24 12:00 ET
No Data
No Data